How small cell lung cancer fixes DNA damage during treatment
Repair Mechanisms of Replication fork Lesions in SCLC
Researchers are looking at how small cell lung cancer cells get and repair DNA damage during therapy to understand why some tumors respond and others become resistant.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11171396 on NIH RePORTER |
What this research studies
This project looks at the specific kinds of DNA damage that happen when small cell lung cancer cells copy their DNA and how those lesions are fixed. Scientists will compare tumors and cell models that are treatment-naïve with ones that have become therapy-resistant to see what changes. The work uses cellular experiments and sensitive single-molecule assays to map damage types and repair steps, and will test how new targeted drugs affect those processes. Findings could point to weak spots in resistant tumors that new treatments might exploit.
Who could benefit from this research
Good fit: People with a diagnosis of small cell lung cancer, especially those willing to provide tumor samples or consider future trials based on these findings, would be the most relevant candidates.
Not a fit: Patients without small cell lung cancer or those seeking an immediate change to their current clinical care are unlikely to see direct short-term benefits from this basic/translational research.
Why it matters
Potential benefit: If successful, this work could reveal repair weaknesses in small cell lung cancer that lead to better-targeted therapies and improved responses for patients.
How similar studies have performed: Targeting DNA repair has helped in other cancers, but applying detailed replication-fork and single-molecule approaches specifically to small cell lung cancer is relatively new.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Rothenberg, Eli — New York University School of Medicine
- Study coordinator: Rothenberg, Eli
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.